Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Juan Li, Aiqin Gao, Fang Zhang, Shuyun Wang, Jingnan Wang, Jing Wang, Shuyi Han, Zijiang Yang, Xiaozheng Chen, Yuying Fang, Guosheng Jiang, Yuping Sun
Summary: ILT3, an immunosuppressive molecule, is enriched in NSCLC cells and promotes tumor cell migration, invasion, and angiogenesis, potentially serving as a poor prognostic factor for NSCLC patients.
Review
Oncology
Jamie E. Chaft, Andreas Rimner, Walter Weder, Christopher G. Azzoli, Mark G. Kris, Tina Cascone
Summary: The treatment goal for early-stage lung cancer patients is cure, with surgical resection or radiotherapy as definitive local treatments along with adjuvant therapy to improve the likelihood of cure. New therapies lag behind due to inefficient trial designs and lengthy follow-ups, despite efforts to study surrogate endpoints to shorten trial durations.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Article
Plant Sciences
Kaili Lin, Lijuan Huang, Yu Zhang, Minshan Chen, Zhan Li, Ken Kin Lam Yung, Sha Lv, Qianrong Pan, Weisong Zhang, Jijun Fu, Wanshan Li, Qiudi Deng
Summary: Angiogenesis and vasculogenic mimicry play crucial roles in the growth and metastasis of NSCLC. Current angiogenesis inhibitors mainly target endothelial cell-mediated angiogenesis, leaving tumor cell-mediated VM unaddressed. Scoparasin B, a compound derived from a marine fungus, showed strong inhibition effects on both angiogenesis and VM in vitro and in vivo. It effectively suppressed tumor growth, angiogenesis, and VM in a xenograft model, likely by reducing VEGF-A levels and inhibiting the VEGF-A/VEGFR2 signaling pathway. These findings highlight the potential of scoparasin B as a novel angiogenesis inhibitor and suggest the exploration of more natural product-based angiogenesis inhibitors.
JOURNAL OF NATURAL PRODUCTS
(2023)
Article
Oncology
Percy Lee, Billy W. Loo Jr, Tithi Biswas, George X. Ding, Issam M. El Naqa, Andrew Jackson, Feng-Ming Kong, Tamara LaCouture, Moyed Miften, Timothy Solberg, Wolfgang A. Tome, An Tai, Ellen Yorke, X. Allen Li
Summary: Based on the evaluation of published experiences with SBRT, a steep dose-response relationship exists with high rates of durable local control for early-stage non-small cell lung cancer when physical doses of 43-50 Gy are delivered.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Nick Pavlakis
Summary: The management of advanced lung cancer has been transformed by the identification of targetable oncogenic driver alterations, including ALK gene rearrangements. ALK tyrosine kinase inhibitors have become the first-line treatment options for advanced ALK rearranged NSCLC. However, drug resistance remains a challenge, and the role of anti-angiogenic therapy in ALK rearranged NSCLC needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Rui Xue, Yuqiao Sheng, Xixi Duan, Yang Yang, Shengli Ma, Jingjing Xu, Na Wei, Xiaoping Shang, Feng Li, Jiajia Wan, Zhihai Qin
Summary: The study found that the frequency of TEMs in the peripheral blood of lung cancer patients was significantly higher than in patients with benign pulmonary disease and healthy controls, and was positively correlated with NSCLC recurrence and microvascular density. A high TEM frequency was associated with poor overall survival. Circulating TEM frequency may serve as a diagnostic marker for NSCLC.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, Rami Manochakian, Yujie Zhao, Yanyan Lou
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with non-small-cell lung cancer (NSCLC) being the most common type. Although targeted therapy has improved survival in NSCLC patients with actionable mutations, therapy resistance and lack of targeted agents for certain oncogenic driver mutations remain challenges. This review summarizes emerging targeted therapies that have been tested in first-in-human clinical trials in the past year.
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Review
Oncology
H. Adderley, F. H. Blackhall, C. R. Lindsay
Summary: Treatment stratification in stage IV NSCLC is guided by oncogene driver mutations, with a focus on small molecule therapy and immune checkpoint inhibitors. Proper sequencing of therapy is crucial for safe and effective treatment delivery.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Wenjuan Liu, Bingli Zuo, Wenting Liu, Yanfei Huo, Nasha Zhang, Ming Yang
Summary: Lung cancer has the highest mortality and morbidity rates worldwide. The current treatment options are not very effective, and there is a need for the discovery of new biomarkers and therapeutic targets for early diagnosis and improved treatment outcomes. Recent studies have found that long noncoding RNAs have diagnostic and prognostic value in non-small cell lung cancer treatment.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)